Sunday November 8 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Neuroectodermal Tumors

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Neuroectodermal Tumors:

Pubmed Logo
[Primitive neuroectodermal tumor (PNET) of the upper-urinary tract]
Primitive neuroectodermal tumors (PNETs) are rare and aggressive malignant...
30th October, 2009
Service d'urologie, hopital militaire d'instruction Mohammed-V, Hay-Riad, Prog Urol. 2009 Sep;19(8):579-81. Epub 2009 Apr 3.
DOI Direct Link
Mouse models of CNS embryonal tumors.
Central nervous system (CNS) embryonal tumors are devastating cancers in...
27th October, 2009
Neurosurgery Division, National Cancer Center Hospital, 5-1-1, Tsukiji, Brain Tumor Pathol. 2009;26(2):43-50. Epub 2009 Oct 27.
DOI Direct Link
Peripheral primitive neuroectodermal tumor of the urinary bladder in an Arab woman with history of squamous cell carcinoma: a case report.
INTRODUCTION: Peripheral primitive neuroectodermal tumors of the urinary...
16th October, 2009
J Med Case Reports. 2009 Apr 29;3:6840.
DOI Direct Link
Primitive neuroectodermal tumor of the kidney in an adult: a case report.
INTRODUCTION: Primitive neuroectodermal tumors (PNETs) occur predominantly...
16th October, 2009
Cases J. 2009 Jun 5;2:6791.
DOI Direct Link
The utility of FOXO1 fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded specimens in the diagnosis of alveolar rhabdomyosarcoma.
Alveolar rhabdomyosarcoma (ARMS) is an aggressive neoplasm with unique...
16th October, 2009
Department of Anatomic, Cleveland Clinic, Cleveland, OH 44195, USA. Diagn Mol Pathol. 2009 Sep;18(3):138-43.
DOI Direct Link

View more research publications.

Press Releases About Neuroectodermal Tumors:

BioPortfolio Logo
AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2nd November, 2009 AETERNA ZENTARIS INC.
Preliminary evaluation after completion of treatment phase shows that primary efficacy endpoint has been met for patients with advanced-stage platinum-resistant, taxane-pretreated ovarian
Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 26th October, 2009 Reportlinker
-- A focus on "engineered" antibodies Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
Ascenta Therapeutics Announces Presentation of Results From a Dose-Ranging Study of AT-101 With Standard Therapy in Patients With Glioblastoma Multiforme 26th October, 2009 Ascenta Therapeutics, Inc.
MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral,
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer 23rd October, 2009 Onyx Pharmaceuticals, Inc.
WAYNE, N.J. and EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun
NexGenix Pharmaceuticals Awarded Phase I Grant from the National Institute of Neurological Disorders and Stroke (NINDS) Small Business Innovation Research Program (SBIR) for the Development of Novel Small Molecule Hsp90 Therapeutics to Treat Glioma 22nd October, 2009 NexGenix Pharmaceuticals Holdings, Inc.
NEW YORK, Oct. 22 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. a privately-held biotechnology company with a portfolio of novel targeted therapies for oncology and neurodegenerative

Neuroectodermal Tumors Clinical Trials:

Clinical Trials Logo
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors

Neuroectodermal Tumors Patents:

USPTO Logo
US Patent No.Title
7312205 Methods and compositions for inhibiting tumor growth
7407967 Cyclopamine analogues and methods of use thereof
7408021 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
7411051 Antibodies to HDPPA04 polypeptide
7413737 Anti-hydroxylase antibodies and uses thereof

View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Neuroectodermal Tumors scientists - we have details of around 322 individuals working on Neuroectodermal Tumors .


This page has been viewed 363 times
Recent Search Terms used to find this page: PNET uterine tumors treatment | btla license | methods mol biol 2009 472 323 42 | methods mol biol 2009 472 323-42 | neuroectodermal tumors | neuroectodermal tumors | neuroectodermal tumors | neuroectodermal tumors | what is neuroectodermal tumors | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Neuroectodermal Tumors across BioPortfolio, or for Neuroectodermal Tumors Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.